Overview
A structured clinical framework designed to optimize post-surgical recovery and enhance wound healing across all biological phases: inflammation, proliferation, and remodeling. This protocol integrates angiogenic peptides, collagen-stimulating compounds, immune modulators, and growth hormone secretagogues to accelerate tissue regeneration, improve vascularization, and reduce the risk of delayed or chronic wound healing.
Clinical Targets
| Post-operative recovery |
| Chronic non-healing wounds |
| Diabetic wounds |
| Surgical incision healing |
| Skin graft integration support |
Expected Outcomes
| Accelerated wound closure |
| Improved angiogenesis and tissue perfusion |
| Enhanced collagen I and III synthesis |
| Reduced inflammatory burden |
| Improved structural integrity during remodeling phase |
Core Stack
BPC-157
| Administration Route: Subcutaneous (SubQ), perilesional |
| Dose: 250–500 mcg |
| Frequency: Twice daily |
| Duration: 6–8 weeks |
TB-500 (Thymosin β4)
| Administration Route: SubQ |
| Dose: 1.0–2.0 mg |
| Frequency: Twice weekly (loading), then weekly (maintenance) |
| Duration: 8–12 weeks |
GHK-Cu
| Administration Route: SubQ or Topical |
| Dose: 1–3 mg (SubQ) or topical formulation |
| Frequency: Daily |
| Duration: 8–12 weeks |
Enhanced Stack (if indicated)
Thymosin α1 (Tα1)
| Administration Route: SubQ |
| Dose: 1.6 mg |
| Frequency: Twice weekly |
| Duration: 6–8 weeks |
CJC-1295 / Ipamorelin
| Administration Route: SubQ |
| Dose: 100 mcg / 100 mcg |
| Frequency: Once daily (evening) |
| Duration: 8–12 weeks |
KPV
| Administration Route: SubQ or Topical |
| Dose: 200–500 mcg |
| Frequency: Daily |
| Duration: 4–6 weeks |
Phase Structure
Pre-Surgical Optimization (Elective Cases)
| Duration: 2 weeks prior to procedure |
| BPC-157: 250 mcg twice daily |
| GHK-Cu: Topical daily |
| CJC-1295 / Ipamorelin: Nightly to optimize GH elevation |
Acute Post-Operative Phase (Weeks 1–3)
| BPC-157: 500 mcg twice daily near incision |
| TB-500: Twice weekly loading |
| GHK-Cu: SubQ plus topical support |
| KPV: Daily for inflammatory control |
Proliferative Phase (Weeks 4–8)
| Maintain BPC-157 |
| TB-500: Weekly maintenance |
| Continue GHK-Cu |
| Tα1: Twice weekly (if enhanced stack used) |
| CJC-1295 / Ipamorelin: Nightly |
Remodeling Phase (Weeks 9–12)
| Taper BPC-157 to once daily, then discontinue |
| Transition GHK-Cu to topical-only maintenance |
| Maintain CJC-1295 / Ipamorelin if remodeling support needed |
| Discontinue TB-500 |
Rationale
This protocol targets all three phases of wound healing simultaneously. BPC-157 supports angiogenesis and VEGF expression to establish vascular supply to the wound bed. TB-500 enhances actin-mediated cellular migration into the repair matrix. GHK-Cu stimulates collagen synthesis and glycosaminoglycan production while attracting reparative stem cells. Thymosin α1 modulates immune surveillance to reduce infection risk without excessive inflammation. CJC-1295/Ipamorelin elevates systemic growth hormone and IGF-1, enhancing tissue remodeling during sleep-driven recovery cycles.
Monitoring
| Weekly wound measurement (length × width × depth) |
| Photographic documentation |
| Assessment of infection signs |
| Inflammatory markers (CRP) if clinically indicated |
| IGF-1 monitoring if GH secretagogues are used |
Contraindications
| Active malignancy |
| Pregnancy or breastfeeding |
| Uncontrolled systemic infection |
| Severe hepatic or renal impairment |
| Known hypersensitivity to any compound |
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Clinical Disclaimer
This protocol framework is intended for educational and informational purposes for licensed healthcare professionals. These compounds and protocols are not intended to diagnose, treat, cure, or prevent any disease. Patient-specific evaluation, contraindications, and clinical judgment are required prior to implementation.